Objectives. The aim of this study is to find the most optimal model for providing access to preimplantation
genetic diagnosis (PGD) based on generalization and study for existing foreign experience using countries that
widely practice this type of diagnosis and have significant clinical experience and have passed the time-tested
regulatory framework.
Material. The legal acts and doctrinal sources of Austria, Belgium, Great Britain, Germany, Israel, Canada,
France, Switzerland, and Japan are studied. Methods used: general philosophical, general scientific, private
scientific, special (structural-legal, comparative-legal, formal-legal).
Results. The advantages and disadvantages of each of the models of legal regulation of PGD (the medical
model, the high-risk model and the model of non-interference) are evaluated, the conclusion is substantiated
that it is advisable to build on the combination of these to determine the legal grounds for conducting PGD in
the Russian Federation.
Conclusions. It has been established that it is advisable to introduce elements of the medical model through
the legal definition of lists of monogenic diseases and chromosomal abnormalities that are the basis for PGD,
which will eliminate legal uncertainties in understanding and regulating this procedure and provide access
to this type of diagnosis within the framework of IVF programs financed from funds Compulsory medical
insurance. The implementation of elements of a high-risk model is proposed in conjunction with mechanisms
for authorizing PGD for special cases, including the assessment of additional risks in the presence of a major
serious genetic disease or indications for determining the risks of aneuploidy. It has been argued that a variable
assessment of the conditions for conducting PGD should be provided normatively and include the possibility
of proactively authorizing this type of diagnosis at the expense of patients for gene mutations with a relatively
low risk of transmission, diseases with incomplete penetrance, and treatable genetic diseases (including, for
example, cancer breast and ovarian cancer, some cardiogenetic disorders), etc.